Zura Bio Q2 FY26 net loss widens to $26.3 million; R&D expense more than doubled to $20.7 million

Reuters2026/08/11 11:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Zura Bio posted a Q2 net loss of USD 26.3 million, or USD 0.21 per share, widening from USD 16 million, or USD 0.17 per share, a year earlier.
RD expense climbed to USD 20.7 million from USD 8.7 million year-on-year, driven by advancing Phase 2 tibulizumab programs.
Cash and cash equivalents rose to USD 205.1 million at June 30, 2026; cash runway expected to extend through at least end-2028.
Enrollment completed in Phase 2 TibuSHIELD (247 participants) and TibuSURE (91); topline data expected in Q4 2026 and H1 2027.
Polymyalgia rheumatica selected as tibulizumab’s third indication; Phase 2 NEXUS-PMR planned to start by end-2026 following supportive FDA feedback.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zura Bio Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260811021983) on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Zura Bio Q2 FY26 net loss widens to $26.3 million; R&D expense more than doubled to $20.7 million

You may also like

Crypto prices